Data from the phase 3b STEP UP trial demonstrate that the 7.2 mg semaglutide dose provides superior weight reduction compared ...

Doctors explain the differences between the Wegovy pill and injection in terms of efficacy, side effects, and more. They ...

A stronger 7.2 mg dose of Wegovy wins FDA approval after a 54-day review, promising greater weight loss for eligible patients ...

FDA authorization of semaglutide 7.2 mg once weekly was supported by two 72-week Phase III programs and reviewed under the Commissioner’s National Priority Voucher, shortening standard timelines. STEP ...

The FDA approved the new injectable Wegovy HD, or “higher dose,” which has about three times as much medication per shot as ...

Novo Nordisk’s 7.2 mg dose of Wegovy will compete against Lilly’s GLP-1 injection.

In today's Pharmaceutical Executive Daily, Novartis agrees to acquire a pan-mutant-selective inhibitor from Synnovation Therapeutics in a deal worth up to $3 billion while Collegium moves to acquire ...

The Food and Drug Administration (FDA) on Thursday approved a higher dose of the Wegovy weight loss drug. The manufacturer, Novo Nordisk, increased the semaglutide injection by 4.8 mg to total 7.2 mg.

The Danish drugmaker said the accelerated approval was based on results from its Step Up trial, which showed 20.7% mean ...

The FDA has approved a new higher-dose version of injectable semaglutide (Wegovy HD, Novo Nordisk) for both weight loss and long-term weight-loss maintenance. The higher dose, 7.2 mg, produced an ...

Semaglutide went off patent in India on March 20, immediately drawing in generic manufacturers with prices starting as low as Rs 220 a shot. A day earlier, Novo Nordisk had secured US FDA approval for ...

In December 2025, the FDA approved the first-ever GLP-1 pill for chronic weight management - Novo Nordisk’s oral formulation ...